Paper · 37081097

Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia.

Sun K and 5 others. Sci Rep, 2023. Cited by 10 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia. Papers, record 37081097. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37081097

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia.; PubMed
Journal: Sci Rep; PubMed
Year: 2023; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/37081097/; PubMed
DOI: https://doi.org/10.1038/s41598-023-33404-8; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC10119119/; PubMed
The journal: https://conductscience.org/library/journal-index/101563288; PubMed
Citations, by iCite: 10; iCite
Relative citation ratio, by iCite: 0.91; iCite
Revised in PubMed: 2023-04-27; PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Sun K	Kang
2	Zhang Z	Zhiqiang
3	Wang D	Dongqin
4	Huang Y	Yinlong
5	Zhang J	Jing
6	Lian C	Chaoqun

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Adenocarcinoma of Lung	Major topic
Lung Neoplasms	Major topic
Humans
Prognosis
Early Detection of Cancer
Hypoxia
Neoplasm Proteins

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	6,157,744	Characterization of a human B lymphocyte-specific antigen.	J Immunol	1980	https://conductscience.org/library/papers/6157744	PubMed
2	25,822,800	Robust enumeration of cell subsets from tissue expression profiles.	Nat Methods	2015	https://conductscience.org/library/papers/25822800	PubMed
3	18,644,974	Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells.	Mol Cancer Res	2008	https://conductscience.org/library/papers/18644974	PubMed
4	27,979,383	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.	Lancet	2017	https://conductscience.org/library/papers/27979383	PubMed
5	26,412,456	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.	N Engl J Med	2015	https://conductscience.org/library/papers/26412456	PubMed
6	29,371,589	Cell death-based treatment of lung adenocarcinoma.	Cell Death Dis	2018	https://conductscience.org/library/papers/29371589	PubMed
7	27,261,907	Epidemiology of Lung Cancer.	Surg Oncol Clin N Am	2016	https://conductscience.org/library/papers/27261907	PubMed
8	32,329,414	KRT6A Promotes EMT and Cancer Stem Cell Transformation in Lung Adenocarcinoma.	Technol Cancer Res Treat	2020	https://conductscience.org/library/papers/32329414	PubMed
9	28,287,611	FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer.	Oncogenesis	2017	https://conductscience.org/library/papers/28287611	PubMed
10	24,634,381	FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.	Clin Cancer Res	2014	https://conductscience.org/library/papers/24634381	PubMed

1 to 10 of 61

See all 61 references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMID	Title	Journal	Year	In Papers	Source
42,444,878	Integrated hypoxia and metabolic gene signature to predict clinical outcomes and therapeutic vulnerabilities in lung adenocarcinoma.	J Thorac Dis	2026	https://conductscience.org/library/papers/42444878	PubMed
41,776,080	Senescent epithelial cells remodel the tumor microenvironment and drive early LUAD progression: a multiomics risk model and single-cell analysis.	Cell Mol Life Sci	2026	https://conductscience.org/library/papers/41776080	PubMed
41,669,263	CYP4B1 inhibits lung adenocarcinoma progression via PI3K/AKT/mTOR pathway: mechanistic insights and development of a CYP4B1-related prognostic signature.	Front Oncol	2025	https://conductscience.org/library/papers/41669263	PubMed
41,648,000	Functional roles of Keratin 6A in disease pathogenesis across cancer and skin disorders.	Exp Biol Med (Maywood)	2026	https://conductscience.org/library/papers/41648000	PubMed
41,083,700	Comprehensive pan-cancer analysis of KRT6A as a prognostic and immune biomarker.	Sci Rep	2025	https://conductscience.org/library/papers/41083700	PubMed
41,044,260	Identification of prognostic genes associated with phase separation in lung adenocarcinoma and construction of prognostic models.	Sci Rep	2025	https://conductscience.org/library/papers/41044260	PubMed
40,102,484	Mechanism of action for Troxerutin targeting the sialylation-related gene EGLN3 for the treatment of LUAD.	Sci Rep	2025	https://conductscience.org/library/papers/40102484	PubMed
40,034,678	A nicotinamide metabolism-related gene signature for predicting immunotherapy response and prognosis in lung adenocarcinoma patients.	PeerJ	2025	https://conductscience.org/library/papers/40034678	PubMed

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
AKT1	207	PubTator's text mining	https://conductscience.org/library/genes/207	NCBI Gene
BRCA1	672	PubTator's text mining	https://conductscience.org/library/genes/672	NCBI Gene
CD274	29,126	PubTator's text mining	https://conductscience.org/library/genes/29126	NCBI Gene
CD4	920	PubTator's text mining	https://conductscience.org/library/genes/920	NCBI Gene
CYP4B1	1,580	PubTator's text mining	https://conductscience.org/library/genes/1580	NCBI Gene
CYP4F3	4,051	PubTator's text mining	https://conductscience.org/library/genes/4051	NCBI Gene
HIF1A	3,091	PubTator's text mining	https://conductscience.org/library/genes/3091	NCBI Gene
IL4	3,565	PubTator's text mining	https://conductscience.org/library/genes/3565	NCBI Gene
KRT20	54,474	PubTator's text mining	https://conductscience.org/library/genes/54474	NCBI Gene
KRT6A	3,853	PubTator's text mining	https://conductscience.org/library/genes/3853	NCBI Gene

1 to 10 of 14

See all 14 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37081097

GET https://conductscience.org/api/papers/v1/37081097/references?page=2

API reference For AI assistants